A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Recruiting now Phase 3 NCT07153471
Run by Eli Lilly and Company · for 18 and older · All sexes
What this study is about
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Who can join (things the study team will check)
✅ You may be able to join if…
- Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
- Have tried at least once to lose weight through diet but were unsuccessful
- Have osteoarthritis of the knee and at least one of the following conditions:
- Be over 50 years old
- Have morning knee stiffness that lasts about 30 minutes
- Have a crackling or grinding sound or feeling in the knee
🚫 You may not be able to join if…
- Have gained or lost more than 11 pounds within 90 days prior to screening
- Have had a surgery for obesity or plan to have one in the next 18 months
- Have an active knee infection
- Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure
- Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening
Where this trial is running
- Arizona Research Center, Phoenix, Arizona, United States
- AMR Clinical, Tempe, Arizona, United States
- Care Access - Huntington Beach, Huntington Beach, California, United States
- Care Access - Thousand Oaks, Thousand Oaks, California, United States
- Legacy Clinical Trials, Colorado Springs, Colorado, United States
- Chase Medical Research, LLC, Waterbury, Connecticut, United States
- Care Access - Decatur, Decatur, Georgia, United States
- North Georgia Clinical Research, Woodstock, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- AMR Clinical, Newton, Kansas, United States
- MedVadis Research Corporation, Waltham, Massachusetts, United States
- StudyMetrix Research, City of Saint Peters, Missouri, United States
+ 83 more sites.
Who to contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07153471.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.